Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia;Şizofrenide metabolik sendrom sikliǧi, metabolik sendromun ozellikleri ve kullanilan antipsikotiklerle ilişkisi

Noropsikiyatri Arsivi

Volumn 46, Issue 1, 2009, Pages 13-18

  Kaya, Mehmet Cemal ^a   Virit, Osman ^a   Altindaǧ, Abdurrahman ^a   Selek, Salih ^b   Bülbül, Feridun ^a   Bulut, Mahmut ^a   Savaş, Haluk A ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Kahramanmaras Devlet Hastanesi   (Turkey)

Author keywords

Antipsychotics; Metabolic syndrome; Schizophrenia

Indexed keywords

BIPERIDEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE; ARTERIAL PRESSURE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; ONSET AGE; PREVALENCE; SCHIZOPHRENIA; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 63749088975     PISSN: 13000667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Haffner SM, Valdez RA, Hazuda HP et al. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992; 41: 715-22.
2. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-14.
3. Morrow DA, Ridker PM. C-reaktive protein, inflammation and coronary risk. Med Clin North Am 2000; 84: 149-61.
4. Dekker JM, Girman C, Rhodes T et al. Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study. Circulation 2005; 112: 666-73.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-7.
6. Grundy SM, Brewer B, Cleeman JL ve ark. Definition of metabolic syndrome: report of the national heart, lung and blood institude/ american heart association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
7. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, Brussels, 2005.
8. Cerit C, Özten E, Yildiz M. Şizofreni hastalannda Metabolik Sendrom sikliǧi ve ilişkili etmenler. Turk Psikiyatri Derg 2008; 19: 124-32.
9. Mete L, Ünsal PÇ. Yenin Kuşak Antipsikotiklerin Metabolik Yan Etkileri. Klinik Psikofarmakoloji Bülteni 2004; 14: 168-77.
10. By Mayo clinic staff. Metabolic syndrome and risk factors. Mayo foundation for medical education and research 2004; 37: 454-74.
11. Toalson P, Ahmed S, Hardy T ve ark. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 2004; 6: 152-8.
12. Altindaǧ A, Demirbaǧ R, Saraçoǧlu G. Metabolik Sendromda Yaşam Kalitesi: Komorbid Psikiyatrik Bozukluklarin Etkisi. Türkiye'de Psikiyatri 2008; 10: 29-33.
13. Vural M. Şizofreni ve bipolar affektif bozukluk hastalarinda antipsikotik ilaç kullanimi ile Metabolik Sendrom ve diǧer metabolik süreçlerin ilişkisinin incelenmesi. Yayinlanmamiş. Uzmanlik Tezi, Istanbul, Haydarpaşa Numune Eǧitim ve Araştirma Hastanesi, Psikiyatri Kliniǧi, 2007.
14. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005; 118: 15-22.
15. Ito MK. The metabolic syndrome: pathophysiology, clinical relevance and use of niacin. Ann Pharmacother 2004; 38: 277-85.
16. Boke O, Aker S, Sarisoy G ve ark. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008; 38: 103-12.
17. McEvoy JP, Meyer JM, Goff DC ve ark. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
18. De Hert MA, Winkel RV, Eyck DV ve ark. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizoph Res 2006; 83: 87-93.
19. Meyer J, Loh C, Leckband SG ve ark. Prevalence of the metabolic syndrome in Veterans with schizophrenia. Journal of Psychiatric Practice 2006; 12: 5-10.
20. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clinical Psychiatry 2007; 68: 20-7.
21. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sciences 2002; 71: 239-57.
22. Correl CU, Frederickson AM, Kane JM ve ark. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67: 575-83.
23. Bakos CD, Berecz R, Degrell I. Effect of atypical antipsychotics on metabolism. Neuropsychopharma Col Hung 2004; 6: 86-9.
24. Semiz S, Bican M, Çakaloz I ve ark. Çocukluk çaǧi obezitesinde metabolik sendrom prevelansi. 50. Milli Pediatri Kongresi, (08-12 Kasim 2006, Aksu-Antalya), Tarn Metin Kitabi, 2006, s.112-5.
25. Van Gaal LF. Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity. European Neuropsychopharmacology 2006; 16: 142-8.
26. Kozan O, Oguz A, Abaci A ve ark. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548-53.
27. Onat A, Ceyhan K, Sansoy V ve ark. Erişkinlerimizin yarisinda bulunan dislipidemi ve metabolik sendromun özellikleri ve kombine hiperlipidemi ile ilişkisi: ayni zamanda plazma TG düzeyi üst siniri konusunda bir katki. Türk Kardiyoloji Derneǧi Aršivi 2001; 29: 274-85.
28. Gemalmaz A, Aydin S, Başak O ve ark. Prevalence of the Metabolic Syndrome in a Rural Turkish Population: Comparison and Concordance of Two Diagnostic Criteria. Turk J Med Sci 2008; 38: 159-65.
29. Kurt E, Altinbaş K, Alataş G ve ark. Kronik Psikiyatrik Hasta Servislerinde Tedavi Görmekte Olan Şizofreni Hastalarinda Metabolik Sendrom Sikliǧi. Türkiye'de Psikiyatri 2007; 3: 141-5.
30. Öyekçin DG. Bir grup şizofreni ve şizoaffektif bozukluk hastasinda metabolik sendrom sikliǧi. Anadolu Psikiyatri Dergisi 2009; 10: 26-33.
31. Nurkalem Z, Orhan AL, Alper AT ve ark. Akut koroner sendromlu, diyabetik olmayan hastalarda metabolik sendrom ile TIMI risk skoru arasindaki ilişki. Türk Kardiyol Dern Arfl - Arch Turk Soc Cardiol 2007; 35: 231-6.
32. Kato MM, Currier MB, Gomez CM ve ark. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004; 6: 74-7.
33. Straker D, Correll CU, Kramer-Ginsberg E ve ark. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162: 1217-21.
34. Onat A, Sansoy V; Halkimizda koroner hastaliǧin başsuçlusu metabolik sendrom: sikliǧi, unsurlari, koroner risk ile ilişkisi ve yüksek risk kriterleri. Türk Kardiyol Dern Arş 2002; 30: 8-15.
35. Yumru M, Savas HA, Kurt E ve ark. Atypical antipsychotic related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98: 247-52.
36. Heiskanen T, Niskanen L, Lyytikainen R ve ark. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-9.
37. Hagg S, Lindblom Y, Mjörndal T. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93-8.
38. Bermudes RA, Keck PE Jr, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics 2006; 47: 491-7.
39. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24: 7-14.
40. Altinbaş K, Kurt E, Oral ET. Ikinci kuşak antipsikotiklerin endokrin yan etkileri: istisna mi, kural mi?. Anadolu Psikiyatri Dergisi 2005; 6: 259-266.
41. Correl CU, Fredericson AM, Kane JM ve ark. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100.
42. Hummer M, Kemmler G, Kirz M. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5: 437-40.
43. Kinon BJ, Basson BR, Glimore JA ve ark. Longterm olanzapine treatmend: Weight related Health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.
44. Lee E, Leung CM, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry 2004; 65: 864-6.